Achieve Life Sciences, Inc. beat EPS estimates 44% of the time across 16 reported quarters (7 beats, 9 misses), averaging -6.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.18 | $-0.28 | -55.6% | Miss | |
| Q1 FY26 | $-0.30 | $-0.19 | +36.7% | Beat | |
| Q4 FY25 | $-0.27 | $-0.28 | -3.7% | Miss | |
| Q3 FY25 | $-0.24 | $-0.28 | -16.7% | Miss | |
| Q2 FY25 | $-0.37 | $-0.37 | +0.0% | Beat | |
| Q1 FY25 | $-0.37 | $-0.37 | +0.0% | Beat | Q1 FY25 call · transcript |
| Q4 FY24 | $-0.30 | $-0.36 | -20.0% | Miss | |
| Q3 FY24 | $-0.26 | $-0.36 | -38.5% | Miss | |
| Q2 FY24 | $-0.22 | $-0.25 | -13.6% | Miss | |
| Q1 FY24 | $-0.24 | $-0.26 | -8.3% | Miss | |
| Q4 FY23 | $-0.32 | $-0.26 | +18.8% | Beat | |
| Q3 FY23 | $-0.34 | $-0.34 | +0.0% | Beat |
Back to ACHV overview · ACHV holders · ACHV KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.